RVMD
Revolution Medicines (RVMD) surged 20% overnight after announcing it is preparing an FDA filing for...
Article Summary
HOLD- Revolution Medicines (RVMD) surged 20% overnight after announcing it is preparing an FDA filing for Daraxonrasib, a pancreatic cancer treatment that became the first drug to push median survival beyond a year in a Phase 3 trial for the disease, with patients receiving the drug living median of 13.2 months compared with 6.7 months for standard chemotherapy, with the drug reducing risk of death by 60% and improving median overall survival to more than one year, not previously reported in any Phase 3 clinical trial in any line of therapy for this disease.
- Revolution Medicines is advancing a rolling NDA submission and is planning global regulatory filings under a Commissioner's National Priority Voucher, while the FDA authorized an expanded access protocol for eligible patients, allowing them to receive the therapy before potential approval.
- The 500-patient global study tested once-daily DaraxOnRasib against standard chemotherapy in patients with previously treated metastatic PDAC, with or without an identified tumor RAS mutation, and showed patients received a median of 7.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -100.0% | 25% | 0.0 ptsDeclining (-100.0%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 27.9% | 25% | 80.0 ptsVery Good (27.9%) - Good outlook |
| Target Price Upside ? | 17.0% | 20% | 60.0 ptsModerate Upside (17.0%) - Target: $184.29 vs Current: $157.48 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | 0.8% | 15% | 20.0 ptsBarely a Dip (0.8%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About RVMD
- Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
- The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
- Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
- Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.